Literature DB >> 27536188

High-grade glioma management and response assessment-recent advances and current challenges.

M N Khan1, A M Sharma2, M Pitz3, S K Loewen2, H Quon2, A Poulin4, M Essig1.   

Abstract

The management of high-grade gliomas (hggs) is complex and ever-evolving. The standard of care for the treatment of hggs consists of surgery, chemotherapy, and radiotherapy. However, treatment options are influenced by multiple factors such as patient age and performance status, extent of tumour resection, biomarker profile, and tumour histology and grade. Follow-up cranial magnetic resonance imaging (mri) to differentiate treatment response from treatment effect can be challenging and affects clinical decision-making. An assortment of advanced radiologic techniques-including perfusion imaging with dynamic susceptibility contrast mri, dynamic contrast-enhanced mri, diffusion-weighted imaging, proton spectroscopy, mri subtraction imaging, and amino acid radiotracer imaging-can now incorporate novel physiologic data, providing new methods to help characterize tumour progression, pseudoprogression, and pseudoresponse. In the present review, we provide an overview of current treatment options for hgg and summarize recent advances and challenges in imaging technology.

Entities:  

Keywords:  Gliomas; diffusion; perfusion; pseudoprogression; pseudoresponse

Year:  2016        PMID: 27536188      PMCID: PMC4974045          DOI: 10.3747/co.23.3082

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  67 in total

Review 1.  Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.

Authors:  Isaac Yang; Nancy G Huh; Zachary A Smith; Seunggu J Han; Andrew T Parsa
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 2.  Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas.

Authors:  Jerrold L Boxerman; Benjamin M Ellingson
Journal:  Top Magn Reson Imaging       Date:  2015-06

3.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

Review 4.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.

Authors:  Elena Y Dobrikova; Trevor Broadt; Judith Poiley-Nelson; Xiaoyi Yang; Gopalan Soman; Steve Giardina; Ray Harris; Matthias Gromeier
Journal:  Mol Ther       Date:  2008-09-02       Impact factor: 11.454

8.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

View more
  13 in total

Review 1.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

2.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

3.  Adult IDH wild-type lower-grade gliomas should be further stratified.

Authors:  Abudumijit Aibaidula; Aden Ka-Yin Chan; Zhifeng Shi; Yanxi Li; Ruiqi Zhang; Rui Yang; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Yu Yao; Liangfu Zhou; Jinsong Wu; Hong Chen; Ho-Keung Ng
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

4.  Monoexponential, biexponential and stretched exponential models of diffusion weighted magnetic resonance imaging in glioma in relation to histopathologic grade and Ki-67 labeling index using high B values.

Authors:  Nabin Chaudhary; Guiling Zhang; Shihui Li; Wenzhen Zhu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

5.  Differential radiation response between normal astrocytes and glioma cells revealed by comparative transcriptome analysis.

Authors:  Liang Gong; Jiacheng Gu; Jianwei Ge; Xiang Wu; Chao Zhang; Chun Yang; Weiji Weng; Guoyi Gao; Junfeng Feng; Qing Mao
Journal:  Onco Targets Ther       Date:  2017-12-04       Impact factor: 4.147

Review 6.  Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.

Authors:  Junfeng Zhang; Heng Liu; Haipeng Tong; Sumei Wang; Yizeng Yang; Gang Liu; Weiguo Zhang
Journal:  Contrast Media Mol Imaging       Date:  2017-03-20       Impact factor: 3.161

7.  FDPS promotes glioma growth and macrophage recruitment by regulating CCL20 via Wnt/β-catenin signalling pathway.

Authors:  Zhuo Chen; Guangyong Chen; Hang Zhao
Journal:  J Cell Mol Med       Date:  2020-06-28       Impact factor: 5.310

8.  Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression.

Authors:  Ankur M Sharma; Michael Willcock; Oliver Bucher; Thelina Amaratunga; M Nazir Khan; Shaun K Loewen; Harvey Quon; Marco Essig; Marshall Pitz
Journal:  Neurooncol Pract       Date:  2018-05-21

9.  Meta-analysis of the diagnostic performance of diffusion magnetic resonance imaging with apparent diffusion coefficient measurements for differentiating glioma recurrence from pseudoprogression.

Authors:  Yang Yu; Yue Ma; Mengyao Sun; Wenyan Jiang; Tingting Yuan; Dan Tong
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

10.  Three-dimensional visualization of brain tumor progression based accurate segmentation via comparative holographic projection.

Authors:  Rania M Abdelazeem; Doaa Youssef; Jala El-Azab; Salah Hassab-Elnaby; Mostafa Agour
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.